ATE412734T1 - Verfahren zur in vito vorbehandlung von myoblasten vor deren transplantation - Google Patents

Verfahren zur in vito vorbehandlung von myoblasten vor deren transplantation

Info

Publication number
ATE412734T1
ATE412734T1 AT96905630T AT96905630T ATE412734T1 AT E412734 T1 ATE412734 T1 AT E412734T1 AT 96905630 T AT96905630 T AT 96905630T AT 96905630 T AT96905630 T AT 96905630T AT E412734 T1 ATE412734 T1 AT E412734T1
Authority
AT
Austria
Prior art keywords
transplantation
myoblasts
preconditioning
vito
pretreatment
Prior art date
Application number
AT96905630T
Other languages
English (en)
Inventor
Jacques Tremblay
Original Assignee
Univ Laval
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Laval filed Critical Univ Laval
Application granted granted Critical
Publication of ATE412734T1 publication Critical patent/ATE412734T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0658—Skeletal muscle cells, e.g. myocytes, myotubes, myoblasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
AT96905630T 1995-03-16 1996-03-15 Verfahren zur in vito vorbehandlung von myoblasten vor deren transplantation ATE412734T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/404,888 US5833978A (en) 1995-03-16 1995-03-16 Method of in vitro preconditioning healthy donor's myoblasts before transplantation thereof in compatible patients suffering of recessive myopathies like muscular dystrophy, for improving transplantation success

Publications (1)

Publication Number Publication Date
ATE412734T1 true ATE412734T1 (de) 2008-11-15

Family

ID=23601451

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96905630T ATE412734T1 (de) 1995-03-16 1996-03-15 Verfahren zur in vito vorbehandlung von myoblasten vor deren transplantation

Country Status (7)

Country Link
US (2) US5833978A (de)
EP (1) EP0815205B1 (de)
AT (1) ATE412734T1 (de)
AU (1) AU4934496A (de)
CA (1) CA2215244C (de)
DE (1) DE69637730D1 (de)
WO (1) WO1996028541A1 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6410320B1 (en) 1992-03-02 2002-06-25 The University Of Michigan Method and compositions for isolation and growth of kidney tubule stem cells, in vitro kidney tubulogenesis and ex vivo construction of renal tubules
US20020164313A1 (en) * 1995-03-16 2002-11-07 Tremblay Jacques P. Compositions comprising preconditioned myoblasts having enhanced fusion properties
US6150164A (en) 1996-09-30 2000-11-21 The Regents Of The University Of Michigan Methods and compositions of a bioartificial kidney suitable for use in vivo or ex vivo
EP0946713B1 (de) * 1996-10-18 2007-03-07 Universite Laval Verfahren zur in vitro vorbehandlung von myoblasten in der transplantation
CA2275436A1 (en) * 1996-12-20 1998-07-02 Curis, Inc. Treatment of mammalian myocardium with morphogen locally, or with morphogenically-treated myogenic precursor cells
WO1999030730A1 (en) * 1997-12-15 1999-06-24 Universite Laval Methods and compositions for improving the success of cell transplantation in a host
US20030129750A1 (en) * 1998-02-05 2003-07-10 Yitzhack Schwartz Homing of donor cells to a target zone in tissue using active therapeutics or substances
US20030113303A1 (en) * 1998-02-05 2003-06-19 Yitzhack Schwartz Homing of embryonic stem cells to a target zone in tissue using active therapeutics or substances
US6866842B1 (en) 1998-05-01 2005-03-15 University Of Pittsburgh Muscle-derived cells (MDCs) for treating muscle-or bone-related injury or dysfunction
US7115417B1 (en) 1998-05-01 2006-10-03 Chancellor Michael B Soft tissue and bone augmentation and bulking utilizing muscle-derived progenito compositions, and treatments thereof
US6284242B1 (en) * 1999-04-16 2001-09-04 Regents Of The University Of Michigan Method for enhancing myoblast migration and invasion in the context of gene therapy
AU763021B2 (en) * 1999-09-14 2003-07-10 Children's Medical Center Corporation Isolation of muscle-derived stem cells and uses therefor
AU5159901A (en) * 2000-04-14 2001-10-30 Univ Pittsburgh Soft tissue and bone augmentation and bulking utilizing muscle-derived progenitor cells, compositions and treatments thereof
US6538010B1 (en) * 2000-11-08 2003-03-25 Research Triangle Institute Compounds and methods for promoting smoking cessation
US20020155096A1 (en) * 2001-02-23 2002-10-24 Chancellor Michael B. Rapid preparation of stem cell matrices for use in tissue and organ treatment and repair
US7332330B2 (en) 2001-09-11 2008-02-19 Renamed Biologics, Inc. Device for maintaining vascularization near an implant
US7442546B2 (en) * 2002-03-15 2008-10-28 The Regents Of The University Of Michigan Method of modulating inflammatory response
US20050244384A1 (en) * 2002-04-01 2005-11-03 Law Peter K Cellular transplantation for heart regeneration
US7627373B2 (en) 2002-11-30 2009-12-01 Cardiac Pacemakers, Inc. Method and apparatus for cell and electrical therapy of living tissue
ATE482713T1 (de) * 2003-04-25 2010-10-15 Univ Pittsburgh Von muskeln stammende zellen (mdcs) zur förderung und verbesserung der nervenreparatur und - regeneration
US7840263B2 (en) 2004-02-27 2010-11-23 Cardiac Pacemakers, Inc. Method and apparatus for device controlled gene expression
US7764995B2 (en) 2004-06-07 2010-07-27 Cardiac Pacemakers, Inc. Method and apparatus to modulate cellular regeneration post myocardial infarct
US7828711B2 (en) 2004-08-16 2010-11-09 Cardiac Pacemakers, Inc. Method and apparatus for modulating cellular growth and regeneration using ventricular assist device
US8874204B2 (en) 2004-12-20 2014-10-28 Cardiac Pacemakers, Inc. Implantable medical devices comprising isolated extracellular matrix
US8060219B2 (en) 2004-12-20 2011-11-15 Cardiac Pacemakers, Inc. Epicardial patch including isolated extracellular matrix with pacing electrodes
US7981065B2 (en) 2004-12-20 2011-07-19 Cardiac Pacemakers, Inc. Lead electrode incorporating extracellular matrix
US20060263338A1 (en) * 2005-03-04 2006-11-23 Jacoby Douglas B Catheter-based delivery of Skeletal Myoblasts to the Myocardium of Damaged Hearts
ES2678416T3 (es) * 2007-01-11 2018-08-10 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Células derivadas de músculo para el tratamiento de patologías de las vías urinarias y métodos de fabricación y uso de las mismas
EP2328596B1 (de) * 2008-08-18 2019-03-06 University of Pittsburgh - Of the Commonwealth System of Higher Education Knochenaufbau anhand von vorläuferzusammensetzungen aus muskeln in biokompatibler matrix und behandlungen
US20100233138A1 (en) * 2008-11-07 2010-09-16 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Vocal Cord Augmentation Utilizing Muscle-Derived Progenitor Compositions, and Treatments Thereof
WO2014161405A1 (en) * 2013-04-03 2014-10-09 Gene-Vinate Limited Means and method for expression of authentic human epidermal growth factor and/or basic fibrolast growth factor in cytoplasm and/or culture medium of escherichia coli
US10273520B2 (en) 2013-04-03 2019-04-30 Wan Keung Raymond Wong Means and methods for hyper-production of authentic human basic fibroblast growth factor in Escherichia coli
EP3057599A4 (de) * 2013-10-17 2017-04-19 University of Maryland, Baltimore Verfahren zur erzeugung von reifen menschlichen muskelfasern
EP4538365A3 (de) 2016-03-04 2025-07-30 The Board Of Trustees Of The Leland Stanford Junior University Zusammensetzungen und verfahren zur muskelregeneration mit prostaglandin e2
GB2578539B (en) 2017-06-09 2022-08-10 Univ Leland Stanford Junior Compositions and methods for preventing or treating muscle conditions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5130141A (en) * 1988-05-24 1992-07-14 Law Peter K Compositions for and methods of treating muscle degeneration and weakness
US5143842A (en) * 1988-11-01 1992-09-01 The University Of Colorado Foundation, Inc. Media for normal human muscle satellite cells
WO1991007992A1 (en) * 1989-11-24 1991-06-13 Monash University Proliferative action of leukaemia inhibitory factor on satellite cells

Also Published As

Publication number Publication date
CA2215244C (en) 2009-12-22
AU4934496A (en) 1996-10-02
WO1996028541A1 (en) 1996-09-19
EP0815205B1 (de) 2008-10-29
DE69637730D1 (de) 2008-12-11
EP0815205A1 (de) 1998-01-07
US5833978A (en) 1998-11-10
US20010051148A1 (en) 2001-12-13
CA2215244A1 (en) 1996-09-19

Similar Documents

Publication Publication Date Title
DE69637730D1 (de) Verfahren zur in vito vorbehandlung von myoblasten vor deren transplantation
TW349941B (en) Substituted N-heteroaroylguanidines, a process for their preparation, their use as a medicament or diagnostic agent, and a medicament containing them
IL144559A0 (en) Antibodies for cancer therapy and diagnosis
UA66750C2 (en) Substituted 1-phenylpirazole 3-carboxamides, a method for the preparation thereof and intermediary compounds, pharmaceutical composition having affinity to neurotensin receptors
ID28003A (id) Turunan-turunan adamantana
GEP20002180B (en) Composition and Methods for Stimulating Megakaryocyte Growth and Differentiation
ATE185268T1 (de) Fortschrittliches arzneistoffabgabesystem und verfahren zur behandlung von psychiatrischen, neurologischen und anderen erkrankungen mit carbamazepin
UA32636C2 (uk) Засіб для зниження вмісту холестерину в сироватці крові людини
CA2392284A1 (en) Medical device
AU6628496A (en) Polyether block copolymer micellar compositions for targeting biological agents
PT998287E (pt) Utilizacao de levobupivacaina
EP1342476A3 (de) FGFR3 als Marker für mesenchymale skeletale Vorläuferzellen und Verwendung von cytoxischen Konjugaten enthaltend eine FGFR3 bindende Gruppe für die Behandlung von Tumoren des Knorpels oder des Knochens
AU8502198A (en) Method for treating vascular proliferative diseases with p27 and fusions thereof
DE3773077D1 (de) Immunotoxine, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.
GR3030262T3 (en) Compositions and methods using unbound mpl receptor for stimulating platelet production
EP0547102A4 (de)
IL101675A (en) Method and pharmaceutical compositions for detecting and localizing tissues having neurokinine 1 receptors
AU1200488A (en) Protein c inhibitor (pci) as pharmaceutical and in vitro diagnostic aid, a process for the preparation of a pharmaceutical or diagnostic aid of this type, and an agent containing pci
PT86228A (de) Verfahren zur herstellung von 6alpha,9alpha-difluor-11beta,17alpha-dihydroxy-16alpha-methil-4-pregnen-3,20-dion und dessen derivate
RU96111557A (ru) Способ лечения нейросенсорной тугоухости
IL126158A0 (en) Method for treating substance abuse
UA42749C2 (uk) N,n-діетил-8,8-дипропіл-2-азаспіро[4,5]декан-2-пропанамін дималеат, фармацевтична композиція, спосіб лікування
ZA885625B (en) Therapeutic agents containing enantiomers of propafenone
ATE178493T1 (de) Stabilisierte antikörperfragmente
SU1744810A1 (ru) Вазоактивное средство, нормализующее функции вегетативной нервной системы "димефосфон"

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties